Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Todd A. Fehniger; John C. Byrd; Guido Marcucci; Camille N. Abboud; Cheryl Kefauver; Jacqueline E. Payton; Ravi Vij; William Blum

doi:10.1182/blood-2008-04-152678

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Todd A. Fehniger, John C. Byrd, Guido Marcucci, Camille N. Abboud, Cheryl Kefauver, Jacqueline E. Payton, Ravi Vij, William Blum

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q-chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www. clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.

Original language	English
Pages (from-to)	1002-1005
Number of pages	4
Journal	Blood
Volume	113
Issue number	5
DOIs	https://doi.org/10.1182/blood-2008-04-152678
State	Published - Jan 29 2009

Access to Document

10.1182/blood-2008-04-152678

Cite this

@article{b82b0bdabb0148b788dc17bf5050b4d4,

title = "Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13",

abstract = "Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q-chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www. clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.",

author = "Fehniger, {Todd A.} and Byrd, {John C.} and Guido Marcucci and Abboud, {Camille N.} and Cheryl Kefauver and Payton, {Jacqueline E.} and Ravi Vij and William Blum",

year = "2009",

month = jan,

day = "29",

doi = "10.1182/blood-2008-04-152678",

language = "English",

volume = "113",

pages = "1002--1005",

journal = "Blood",

issn = "0006-4971",

number = "5",

}

TY - JOUR

T1 - Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

AU - Fehniger, Todd A.

AU - Byrd, John C.

AU - Marcucci, Guido

AU - Abboud, Camille N.

AU - Kefauver, Cheryl

AU - Payton, Jacqueline E.

AU - Vij, Ravi

AU - Blum, William

PY - 2009/1/29

Y1 - 2009/1/29

N2 - Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q-chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www. clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.

AB - Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q-chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www. clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.

UR - http://www.scopus.com/inward/record.url?scp=60849098162&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-04-152678

DO - 10.1182/blood-2008-04-152678

M3 - Article

C2 - 18824593

AN - SCOPUS:60849098162

SN - 0006-4971

VL - 113

SP - 1002

EP - 1005

JO - Blood

JF - Blood

IS - 5

ER -

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Abstract

Access to Document

Other files and links

Fingerprint

Cite this